Clinical trials of MRS methods

Margarida Julia-Sape*, Fernando Arias-Mendoza, John R. Griffiths

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

2 Citations (Scopus)


© 2015 John Wiley & Sons, Ltd. In order to determine the applicability of noninvasive magnetic resonance spectroscopy (MRS) to the study of a diseased tissue or organ in the human body, it is necessary to determine if MRS is safe and effective. This is usually the primary purpose of a clinical trial of a novel method. A clinical trial for MRS may also reveal which technical approach works best for the specific application and characteristics of the population being studied. In this article, we discuss the legal, ethical, and scientific requirements to be considered before the start of a clinical trial of an MRS protocol, as well as constraints that may arise during its execution. MRS-specific issues arising from a couple of successful clinical MRS trials for classifying brain tumors with 1H MRS (INTERPRET and eTUMOUR) and body tumors with 31P MRS (the Cooperative Group on MRS Application in Cancer, CoGMAC) serve as illustrative examples.
Original languageEnglish
Pages (from-to)779-788
Number of pages10
Issue number4
Publication statusPublished - 1 Jan 2015


  • artifacts
  • clinical trial
  • MRS
  • multicenter
  • quality control


Dive into the research topics of 'Clinical trials of MRS methods'. Together they form a unique fingerprint.

Cite this